Inactivated aAPCs for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell therapies for cancer treatment, such as adoptive T-cell immunotherapy, face challenges in efficiently activating cytotoxic T cells due to the inefficiency of natural antigen-presenting cells and the lack of reproducible methods for generating antigen-specific CD8+ T cells, which limits their effectiveness in targeting cancer cells.
Innovation Solution
The method involves inactivating artificial antigen-presenting cells (aAPCs) using psoralen derivatives and UVA irradiation, loading them with specific peptide antigens, and contacting T lymphocytes to activate them ex vivo, thereby generating potent antigen-specific cytotoxic T cells for cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If natural antigen-presenting cells are used to activate T cells, then the process is simpler, but the activation efficiency is low and T cell responses are weak
Solution Approach 1:
The patent introduces artificial antigen-presenting cells (aAPCs) as an intermediary system between the vaccine antigen and T cells. These aAPCs are engineered to express specific MHC molecules and co-stimulatory molecules, enabling them to efficiently present tumor-associated antigens to CD8+ T cells and provide necessary co-stimulation signals, thereby overcoming the limitations of natural APCs while maintaining process feasibility
Solution Approach 2:
The patent modifies the functional parameters of antigen-presenting cells by engineering aAPCs to overexpress specific MHC class I molecules and co-stimulatory molecules (CD80, CD86, CD40). This parameter change enables the aAPCs to provide enhanced antigen presentation capacity and co-stimulation signals, directly improving T cell activation efficiency and cytotoxic T cell generation
2Productivity
If aAPCs are made viable for T cell activation, then activation efficiency improves, but safety risks increase due to potential uncontrolled proliferation
Solution Approach 1:
The patent extracts the essential functional components (MHC molecules, co-stimulatory molecules, adhesion molecules) from viable antigen-presenting cells and transfers them onto inert carrier particles. This extraction allows the aAPCs to provide necessary activation signals without retaining the capacity for uncontrolled proliferation, thereby ensuring safety while maintaining T cell activation efficiency
Solution Approach 2:
The patent employs aAPCs based on non-viable carrier particles that cannot replicate or persist long-term in the patient's body. These disposable aAPCs perform their activation function and are then eliminated, avoiding safety risks associated with viable cells while maintaining effective T cell stimulation during the therapeutic window
3Quantity of substance
If high doses of IL-2 are used to expand T cells, then T cell numbers increase, but toxicity to the patient increases
Solution Approach 1:
The patent performs preliminary expansion of antigen-specific CD8+ T cells ex vivo using engineered aAPCs and controlled cytokine stimulation before administration to the patient. This preliminary action generates sufficient numbers of therapeutic T cells in advance, eliminating the need for high-dose IL-2 administration post-infusion and thereby reducing patient toxicity while achieving adequate T cell numbers
Solution Approach 2:
The patent replaces the mechanical/systemic approach of high-dose IL-2 administration with a targeted ex vivo expansion system using engineered aAPCs. This substitution allows precise control over T cell expansion in a contained environment, achieving necessary T cell numbers without the systemic toxicity associated with high-dose cytokine therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the activation and proliferation of antigen-specific CD8+ T cells, improving their cytotoxic activity against cancer cells and potentially leading to more effective cancer treatment outcomes by specifically targeting melanoma and other cancer types.
Implementation Method 1
inactivating artificial antigen presenting cells (aAPCs) by treating the aAPCs with a psoralen derivative and exposing the aAPCs treated with the psoralen derivative to a photoactivating dose of UVA irradiation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation.